The Filings Report

STERIS plc

STENYSECIK 1757898Healthcare / Medical Devicesfiscal year ends March34 quarters since 2018

Revenue, Q1 FY2027
$1.5B
+7.3% on Q1 FY2026
Net income
$200M
+12.8% on Q1 FY2026
Free cash flow
$280M
−14.3% on Q1 FY2026
Diluted EPS
—
not filed for a derived quarter
Revenue, TTM
$6.0B
trailing four quarters
Net margin, TTM
13.3%
net income $805M
Free cash flow, TTM
$926M
$1.3B less $363M capex
Cash and equivalents
$482M
long-term debt $1.7B, Jun 30, 2026
Shares, 12-month change
−1.0%
98M shares, Jun 30, 2026
Buybacks, TTM
$340M
1.5% of market value
Dividends, TTM
$247M
1.1% of market value
Market value
$22.1B
at the close, buybacks

Latest quarter Q1 FY2027, filed August 7, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q1 FY2027, the quarter ended June 30, 2026, STERIS plc reported revenue of $1.5B, +7.3% on Q1 FY2026, and net income of $200M (+12.8%). Operating margin was 19.1%. Free cash flow, operating cash flow less capital expenditures, was $280M ($367M less $88M).

The last 16 quarters

Q2 FY2023 to Q1 FY2027, through the filing of August 7, 2026.

Revenue and net incomeRevenueNet income
−$500M$0$500M$1.0B$1.5B$2.0BQ2'23, Revenue: $1.1BQ2'23, Net income: −$315MQ2'23Q3'23, Revenue: $1.1BQ3'23, Net income: $124MQ3'23Q4'23, Revenue: $1.3BQ4'23, Net income: $187MQ4'23Q1'24, Revenue: $1.2BQ1'24, Net income: $124MQ1'24Q2'24, Revenue: $1.2BQ2'24, Net income: $115MQ2'24Q3'24, Revenue: $1.3BQ3'24, Net income: $141MQ3'24Q4'24, Revenue: $1.4BQ4'24, Net income: −$1MQ4'24Q1'25, Revenue: $1.3BQ1'25, Net income: $145MQ1'25Q2'25, Revenue: $1.3BQ2'25, Net income: $150MQ2'25Q3'25, Revenue: $1.4BQ3'25, Net income: $174MQ3'25Q4'25, Revenue: $1.5BQ4'25, Net income: $146MQ4'25Q1'26, Revenue: $1.4BQ1'26, Net income: $177MQ1'26Q2'26, Revenue: $1.5BQ2'26, Net income: $192MQ2'26Q3'26, Revenue: $1.5BQ3'26, Net income: $193MQ3'26Q4'26, Revenue: $1.6BQ4'26, Net income: $220MQ4'26Q1'27, Revenue: $1.5BQ1'27, Net income: $200MQ1'27−$500M$0$500M$1.0B$1.5B$2.0BQ2'23, Revenue: $1.1BQ2'23, Net income: −$315MQ3'23, Revenue: $1.1BQ3'23, Net income: $124MQ3'23Q4'23, Revenue: $1.3BQ4'23, Net income: $187MQ1'24, Revenue: $1.2BQ1'24, Net income: $124MQ1'24Q2'24, Revenue: $1.2BQ2'24, Net income: $115MQ3'24, Revenue: $1.3BQ3'24, Net income: $141MQ3'24Q4'24, Revenue: $1.4BQ4'24, Net income: −$1MQ1'25, Revenue: $1.3BQ1'25, Net income: $145MQ1'25Q2'25, Revenue: $1.3BQ2'25, Net income: $150MQ3'25, Revenue: $1.4BQ3'25, Net income: $174MQ3'25Q4'25, Revenue: $1.5BQ4'25, Net income: $146MQ1'26, Revenue: $1.4BQ1'26, Net income: $177MQ1'26Q2'26, Revenue: $1.5BQ2'26, Net income: $192MQ3'26, Revenue: $1.5BQ3'26, Net income: $193MQ3'26Q4'26, Revenue: $1.6BQ4'26, Net income: $220MQ1'27, Revenue: $1.5BQ1'27, Net income: $200MQ1'27

Net income losses drawn in red.

Free cash flow
$0$100M$200M$300M$400MQ2'23, Free cash flow: $21MQ2'23Q3'23, Free cash flow: $114MQ3'23Q4'23, Free cash flow: $144MQ4'23Q1'24, Free cash flow: $215MQ1'24Q2'24, Free cash flow: $63MQ2'24Q3'24, Free cash flow: $172MQ3'24Q4'24, Free cash flow: $163MQ4'24Q1'25, Free cash flow: $196MQ1'25Q2'25, Free cash flow: $149MQ2'25Q3'25, Free cash flow: $244MQ3'25Q4'25, Free cash flow: $190MQ4'25Q1'26, Free cash flow: $326MQ1'26Q2'26, Free cash flow: $201MQ2'26Q3'26, Free cash flow: $200MQ3'26Q4'26, Free cash flow: $245MQ4'26Q1'27, Free cash flow: $280MQ1'27$0$100M$200M$300M$400MQ2'23, Free cash flow: $21MQ3'23, Free cash flow: $114MQ3'23Q4'23, Free cash flow: $144MQ1'24, Free cash flow: $215MQ1'24Q2'24, Free cash flow: $63MQ3'24, Free cash flow: $172MQ3'24Q4'24, Free cash flow: $163MQ1'25, Free cash flow: $196MQ1'25Q2'25, Free cash flow: $149MQ3'25, Free cash flow: $244MQ3'25Q4'25, Free cash flow: $190MQ1'26, Free cash flow: $326MQ1'26Q2'26, Free cash flow: $201MQ3'26, Free cash flow: $200MQ3'26Q4'26, Free cash flow: $245MQ1'27, Free cash flow: $280MQ1'27

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$1B$2B$3B$4BQ2'23, Cash and equivalents: $258MQ2'23, Long-term debt: $2.9BQ2'23Q3'23, Cash and equivalents: $259MQ3'23, Long-term debt: $3.0BQ3'23Q4'23, Cash and equivalents: $208MQ4'23, Long-term debt: $3.0BQ4'23Q1'24, Cash and equivalents: $209MQ1'24, Long-term debt: $2.9BQ1'24Q2'24, Cash and equivalents: $214MQ2'24, Long-term debt: $3.4BQ2'24Q3'24, Cash and equivalents: $196MQ3'24, Long-term debt: $3.2BQ3'24Q4'24, Cash and equivalents: $207MQ4'24, Long-term debt: $3.1BQ4'24Q1'25, Cash and equivalents: $198MQ1'25, Long-term debt: $2.2BQ1'25Q2'25, Cash and equivalents: $172MQ2'25, Long-term debt: $2.2BQ2'25Q3'25, Cash and equivalents: $155MQ3'25, Long-term debt: $2.0BQ3'25Q4'25, Cash and equivalents: $172MQ4'25, Long-term debt: $1.9BQ4'25Q1'26, Cash and equivalents: $280MQ1'26, Long-term debt: $1.9BQ1'26Q2'26, Cash and equivalents: $319MQ2'26, Long-term debt: $1.9BQ2'26Q3'26, Cash and equivalents: $424MQ3'26, Long-term debt: $1.9BQ3'26Q4'26, Cash and equivalents: $440MQ4'26, Long-term debt: $1.8BQ4'26Q1'27, Cash and equivalents: $482MQ1'27, Long-term debt: $1.7BQ1'27$0$1B$2B$3B$4BQ2'23, Cash and equivalents: $258MQ2'23, Long-term debt: $2.9BQ3'23, Cash and equivalents: $259MQ3'23, Long-term debt: $3.0BQ3'23Q4'23, Cash and equivalents: $208MQ4'23, Long-term debt: $3.0BQ1'24, Cash and equivalents: $209MQ1'24, Long-term debt: $2.9BQ1'24Q2'24, Cash and equivalents: $214MQ2'24, Long-term debt: $3.4BQ3'24, Cash and equivalents: $196MQ3'24, Long-term debt: $3.2BQ3'24Q4'24, Cash and equivalents: $207MQ4'24, Long-term debt: $3.1BQ1'25, Cash and equivalents: $198MQ1'25, Long-term debt: $2.2BQ1'25Q2'25, Cash and equivalents: $172MQ2'25, Long-term debt: $2.2BQ3'25, Cash and equivalents: $155MQ3'25, Long-term debt: $2.0BQ3'25Q4'25, Cash and equivalents: $172MQ4'25, Long-term debt: $1.9BQ1'26, Cash and equivalents: $280MQ1'26, Long-term debt: $1.9BQ1'26Q2'26, Cash and equivalents: $319MQ2'26, Long-term debt: $1.9BQ3'26, Cash and equivalents: $424MQ3'26, Long-term debt: $1.9BQ3'26Q4'26, Cash and equivalents: $440MQ4'26, Long-term debt: $1.8BQ1'27, Cash and equivalents: $482MQ1'27, Long-term debt: $1.7BQ1'27

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q1 FY2027 filed August 7, 2026.

STERIS plc income statement, quarterly
Millions of dollarsQ1 FY2027ended Jun 30, 2026filed Aug 7, 2026Q4 FY2026ended Mar 31, 2026filed May 29, 2026Q3 FY2026ended Dec 31, 2025filed Feb 6, 2026Q2 FY2026ended Sep 30, 2025filed Nov 6, 2025Q1 FY2026ended Jun 30, 2025filed Aug 7, 2025Q4 FY2025ended Mar 31, 2025filed May 29, 2025Q3 FY2025ended Dec 31, 2024filed Feb 7, 2025Q2 FY2025ended Sep 30, 2024filed Nov 7, 2024YoYQ1 FY2027vs Q1 FY2026
Revenue1,4931,5881,4961,4601,3911,4811,3711,329+7.3%
Cost of revenue809891841814763839760750+6.0%
Gross profit684697656646628641610579+8.9%
Research and development2929302826282727+8.3%
Selling, general and administrative370352352350354334336329+4.5%
Operating income286317273266246216245220+16.2%
Other income (expense)(12)(12)(15)(13)(14)(19)(16)(25)+12.8%
Pretax income274305258253232197229195+17.9%
Income tax7384646154515544+34.5%
Net income200220193192177146174150+12.8%
Diluted EPS ($)——1.961.941.79—1.751.51—
Diluted shares (millions)98—999999—9999—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q1 FY2027 filed August 7, 2026.

STERIS plc balance sheet, quarterly
Millions of dollarsQ1 FY2027ended Jun 30, 2026filed Aug 7, 2026Q4 FY2026ended Mar 31, 2026filed May 29, 2026Q3 FY2026ended Dec 31, 2025filed Feb 6, 2026Q2 FY2026ended Sep 30, 2025filed Nov 6, 2025Q1 FY2026ended Jun 30, 2025filed Aug 7, 2025Q4 FY2025ended Mar 31, 2025filed May 29, 2025Q3 FY2025ended Dec 31, 2024filed Feb 7, 2025Q2 FY2025ended Sep 30, 2024filed Nov 7, 2024YoYQ1 FY2027vs Q1 FY2026
Cash and equivalents482440424319280172155172+72.4%
Short-term investments—————————
Total current assets2,4462,3952,2862,1062,0582,0011,8981,938+18.9%
Total assets10,73610,73710,59110,41110,40510,14710,00810,242+3.2%
Total current liabilities1,2831,1459228899271,022891805+38.5%
Long-term debt1,6501,8131,8981,8971,9031,9192,0392,156−13.3%
Total liabilities3,5153,5403,4243,3883,4353,5313,5803,632+2.3%
Stockholders’ equity7,2077,1847,1557,0096,9576,6036,4166,593+3.6%
Shares outstanding (millions)9898989898989899—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q1 FY2027 filed August 7, 2026.

STERIS plc cash flow statement, quarterly
Millions of dollarsQ1 FY2027ended Jun 30, 2026filed Aug 7, 2026Q4 FY2026ended Mar 31, 2026filed May 29, 2026Q3 FY2026ended Dec 31, 2025filed Feb 6, 2026Q2 FY2026ended Sep 30, 2025filed Nov 6, 2025Q1 FY2026ended Jun 30, 2025filed Aug 7, 2025Q4 FY2025ended Mar 31, 2025filed May 29, 2025Q3 FY2025ended Dec 31, 2024filed Feb 7, 2025Q2 FY2025ended Sep 30, 2024filed Nov 7, 2024YoYQ1 FY2027vs Q1 FY2026
Operating cash flow367335298288420261333251−12.6%
Capital expenditures88909987947189102−6.5%
Free cash flow (CFO − capex)280245200201326190244149−14.3%
Depreciation and amortization124123122122119122126115+3.7%
Share repurchases116745010111010146+989.6%
Dividends paid6162626256565656+9.3%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2026 filed May 29, 2026.

Income statement

STERIS plc income statement, annual
Millions of dollarsFY2026ended Mar 31, 2026filed May 29, 2026FY2025ended Mar 31, 2025filed May 29, 2025FY2024ended Mar 31, 2024filed May 29, 2024FY2023ended Mar 31, 2023filed May 26, 2023FY2022ended Mar 31, 2022filed May 31, 2022FY2021ended Mar 31, 2021filed May 28, 2021FY2020ended Mar 31, 2020filed May 29, 2020FY2019ended Mar 31, 2019filed May 30, 2019FY2018ended Mar 31, 2018filed May 30, 2019FY2017ended Mar 31, 2017filed May 30, 2019
Revenue5,9365,4605,1394,5364,2233,1083,0312,7822,6202,613
Cost of revenue3,3093,0572,9212,5562,3401,7641,7111,6071,5271,587
Gross profit2,6272,4032,2181,9811,8831,3431,3201,1751,0931,026
Research and development11310810498876666636159
Selling, general and administrative1,4081,3341,2521,0911,318731717670632682
Operating income1,102867836791478548537411400226
Other income (expense)(54)(70)(133)(111)(111)(31)(38)(42)(45)(42)
Pretax income1,047796703680367518499369355185
Income tax2621851501248212191646374
Net income782615378107244397408304291110
Diluted EPS ($)7.936.203.811.072.484.634.763.553.391.28
Diluted shares (millions)999999100988686858686

Balance sheet

STERIS plc balance sheet, annual
Millions of dollarsFY2026ended Mar 31, 2026filed May 29, 2026FY2025ended Mar 31, 2025filed May 29, 2025FY2024ended Mar 31, 2024filed May 29, 2024FY2023ended Mar 31, 2023filed May 26, 2023FY2022ended Mar 31, 2022filed May 31, 2022FY2021ended Mar 31, 2021filed May 28, 2021FY2020ended Mar 31, 2020filed May 29, 2020FY2019ended Mar 31, 2019filed May 30, 2019FY2018ended Mar 31, 2018filed May 30, 2019FY2017ended Mar 31, 2017filed May 30, 2019
Cash and equivalents440172207208348221320221202283
Short-term investments——————————
Total current assets2,3952,0012,8692,0111,8791,2121,2241,054990—
Total assets10,73710,14711,06410,82211,4246,5745,4415,0735,200—
Total current liabilities1,1451,022931862922578504465398—
Long-term debt1,8131,9193,1203,0192,9451,6511,1511,1831,316—
Total liabilities3,5403,5314,7484,7354,8792,6832,0231,8871,983—
Stockholders’ equity7,1846,6036,3026,0776,5323,8813,4053,1783,206—
Shares outstanding (millions)98989999100858585——

Cash flow statement

STERIS plc cash flow statement, annual
Millions of dollarsFY2026ended Mar 31, 2026filed May 29, 2026FY2025ended Mar 31, 2025filed May 29, 2025FY2024ended Mar 31, 2024filed May 29, 2024FY2023ended Mar 31, 2023filed May 26, 2023FY2022ended Mar 31, 2022filed May 31, 2022FY2021ended Mar 31, 2021filed May 28, 2021FY2020ended Mar 31, 2020filed May 29, 2020FY2019ended Mar 31, 2019filed May 30, 2019FY2018ended Mar 31, 2018filed May 30, 2019FY2017ended Mar 31, 2017filed May 30, 2019
Operating cash flow1,3411,148973757685690591540458424
Capital expenditures369370360362288239215190165173
Free cash flow (CFO − capex)972778613395397450376350292251
Depreciation and amortization487476565553553219197226178188
Share repurchases23621112309561551816598
Dividends paid24222020118316313412311310393

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$957K
1 sales by 1 insider; officers and directors $957K
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$10M
12 sales by 7 insiders; officers and directors $10M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 1, 2026Burton Karen LSr. Vice Pres., CFOtax withholding228$0.00—12,956Oct 5, 2026
Aug 12, 2026Sohi MohsenDirectoroption exercise4,058$86.23$350K28,363Aug 12, 2026
Aug 12, 2026Sohi MohsenDirectoropen-market sale4,058$235.78$957K24,305Aug 12, 2026
Jul 1, 2026Sohi MohsenDirectoroption exercise3,781$71.40$270K26,142Jul 2, 2026
Jul 1, 2026Sohi MohsenDirectortax withholding1,837$212.30$390K24,305Jul 2, 2026
Jun 15, 2026Zangerle John AdamSr. VP, Gen Counsel, and Sec.open-market sale10b5-11,419$209.28$297K35,259Jun 16, 2026
Jun 5, 2026Carestio Daniel APresident and CEO, Directoropen-market sale10b5-11,374$212.00$291K63,647Jun 8, 2026
Jun 4, 2026Zangerle John AdamSr. VP, Gen Counsel, and Sec.tax withholding401$212.24$85K36,678Jun 8, 2026
Jun 4, 2026Tamaro RenatoV.P. & Corporate Treasurertax withholding65$212.24$14K6,194Jun 8, 2026
Jun 4, 2026Madsen JuliaSr. VP and GM, Life Sciencestax withholding195$212.24$41K12,257Jun 8, 2026
Jun 4, 2026Kohler Kenneth ESVP & GM, ASTtax withholding150$212.24$32K11,332Jun 8, 2026
Jun 4, 2026Fraser Mary ClareSVP & Chief HROtax withholding600$212.24$127K13,716Jun 8, 2026
Jun 4, 2026Carestio Daniel APresident and CEO, Directortax withholding1,889$212.24$401K68,075Jun 8, 2026
Jun 4, 2026Carestio Daniel APresident and CEO, Directoropen-market sale10b5-13,054$214.64$656K65,021Jun 8, 2026
Jun 4, 2026Burton Karen LSr. Vice Pres., CFOtax withholding90$212.24$19K13,184Jun 8, 2026
Jun 3, 2026Zangerle John AdamSr. VP, Gen Counsel, and Sec.tax withholding365$210.19$77K37,079Jun 5, 2026
Jun 3, 2026Tamaro RenatoV.P. & Corporate Treasurertax withholding64$210.19$13K6,259Jun 5, 2026
Jun 3, 2026Madsen JuliaSr. VP and GM, Life Sciencestax withholding239$210.19$50K12,452Jun 5, 2026
Jun 3, 2026Kohler Kenneth ESVP & GM, ASTtax withholding184$210.19$39K11,482Jun 5, 2026
Jun 3, 2026Fraser Mary ClareSVP & Chief HROtax withholding311$210.19$65K14,316Jun 5, 2026
Jun 3, 2026Carestio Daniel APresident and CEO, Directortax withholding2,619$210.19$550K69,964Jun 5, 2026
Jun 3, 2026Burton Karen LSr. Vice Pres., CFOtax withholding190$210.19$40K13,274Jun 5, 2026
Jun 2, 2026Zangerle John AdamSr. VP, Gen Counsel, and Sec.award4,359$0.00—37,691Jun 4, 2026
Jun 2, 2026Zangerle John AdamSr. VP, Gen Counsel, and Sec.tax withholding247$209.76$52K37,444Jun 4, 2026
Jun 2, 2026Tamaro RenatoV.P. & Corporate Treasureraward750$0.00—6,364Jun 4, 2026

Full insider history for STERIS plc, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 3; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
STERIS plc, CIK 1757898 on EDGAR
Extract generated
November 1, 2026
Withheld
7 line-years whose four quarters do not sum to the filed year: cost of revenue FY2018, gross profit FY2018, net income FY2018, revenue FY2018, cost of revenue FY2022, gross profit FY2022, revenue FY2022
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: CostOfGoodsAndServicesSold, CostOfRevenue
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/STE.json